iBio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

Speculators chased IBIO stock up in hopes of a coronavirus vaccine, but long-term investors should stay far away from iBio here. 
The post Don’t Buy iBio Stock for a Coronavirus Vaccine appeared first on InvestorPlace.

Don’t Buy iBio Stock for a Coronavirus Vaccine

iBio stock offers investors an exciting speculative bet. It already showed its potential this year so it could have repeat performance soon.

Don’t Miss the Next Wild Moved in iBio Stock

At the moment, it’s better to just avoid iBio stock. There are far better opportunities to be found in this market.

Avoid iBio Stock In the Near-Term As Competitors Keep Racing Ahead

There has been a lot of noise surrounding IBIO stock. But investors need that noise to turn into actionable news to reverse the stock's trend.

iBio Takes Swings, But Hasn’t Found a Pitch It Can Hit

IBIO stock is a speculative bet that has the potential to double from current levels if there is positive progress related to clinical trials.
The post IBIO Stock Is a Speculative Bet That Can Double appeared first on InvestorPlace.

IBIO Stock Is a Speculative Bet That Can Double

A few months ago, there was lots of optimism for IBIO stock.  But unfortunately, the company has not been able to live up to the lofty expectations.

As iBio Stock Fades, It’s Time to Look Elsewhere for a Vaccine Play

One of the earlier Covid-19 darlings, IBIO stock has shed much of its enthusiasm. However, recent news could move the needle again.

What iBio Did and Didn’t Do Makes It Suddenly Relevant

Ibio recently announced IBIO-201 as its coronavirus vaccine candidate. Despite a long road ahead, it’s good news for IBIO stock.

Here’s Why IBIO’s Choice of IBIO-201 in the Vaccine Race is a Good Thing

iBio Inc. (NYSE: IBIO) has announced that it has selected a vaccine to advance for the prevention of infection by SARS-CoV-2, the coronavirus that causes COVID-19.

iBio Takes Another Big Step in the Fight Against COVID-19

The company is advancing its most-promising vaccine candidate for the novel coronavirus.

Why iBio Stock Is Soaring Today

– IBIO-201 Produced Anti-Spike Neutralizing Antibodies in Pre-Clinical Studies –

iBio to Advance COVID-19 LicKM-Subunit Vaccine Candidate, IBIO-201

If you've been waiting for a catalyst to buy beaten-down IBIO stock, a worldwide licensing deal should convince you to take action.
The post Exclusive Global Agreement Puts a Bullish Slant on iBio appeared first on InvestorPlace.

Exclusive Global Agreement Puts a Bullish Slant on iBio

iBio has had a thrilling 2020. But with its Covid-19 products far from approval, and others ahead, IBIO stock is set for a slump.

iBio Is Losing Ground as the Covid-19 Vaccine Race Heats Up

IBIO stock is delivering heartache and more could be on the way as markets realize the company isn't going to deliver a Covid-19 vaccine.
The post Turn Out the Lights on iBio’s Covid-19 Vaccine Party appeared first on InvestorPlace.

Turn Out the Lights on iBio’s Covid-19 Vaccine Party

iBio's leading vaccine and its therapy appear to be too far behind the competition to generate much revenue for IBIO stock.
The post iBio Is Now Lagging in Another Area appeared first on InvestorPlace.

iBio Is Now Lagging in Another Area

Sure, iBio hopes to win the Covid-19 vaccine race, but right now, IBIO stock investors aren't benefiting from the pursuit.
The post At This Point, iBioPharma Is a Flash in the Pandemic appeared first on InvestorPlace.

At This Point, iBioPharma Is a Flash in the Pandemic

Markets realize that the biotech firm is not close to delivering a vaccine, and IBIO stock is getting punished as a result.
The post iBio’s Time Is Running Out in Vaccine Chase appeared first on InvestorPlace.

iBio’s Time Is Running Out in Vaccine Chase

IBIO stock is a speculative play due to the slow development of its pipeline and its lack of much support from external parties.
The post iBio Is an Afterthought in the Covid-19 Vaccine Race appeared first on InvestorPlace.

iBio Is an Afterthought in the Covid-19 Vaccine Race

The biotech struck a licensing deal for a potential coronavirus treatment.

Why iBio Stock Jumped Today

- Novel anti-SARS-CoV-2 Immunoadhesin to be Produced in iBio’s FastPharming® Manufacturing System - - Novel anti-SARS-CoV-2 Immunoadhesin to be Produced in iBio’s FastPharming® Manufacturing System -

iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic

Both the potential rewards and risks offered by IBIO stock are high. But for Covid-19 vaccine bets, there are better options for investors.

Vaccine Race Also-ran iBio Stock Won’t See Earlier Highs Anytime Soon

So, what's the play here? Too risky to go long (or short), stay far away vaccine play IBIO stock.

Steer Clear of Coronavirus Vaccine Also-Ran iBio Stock

iBio stock ripper higher by 30% on Aug 24. Is it time to buy the stock now?

After a 30% Surge, Is It Time to Buy iBio Stock Again? 

Altimmune

Co-Diagnostics

Novavax

Vaxart

It's not a surprise that all five of these stocks are engaged in the fight against the novel coronavirus.

These 5 Healthcare Stocks Are the Biggest Winners in 2020

iBio is behind others in developing a Covid-19 vaccine and it doesn't have a FastPharming partner. There's diminishing value to IBIO stock.

News for iBio Stock (IBIO)